Jaime R Merchan
Overview
Explore the profile of Jaime R Merchan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choueiri T, Merchan J, Figlin R, Mcdermott D, Arrowsmith E, Michaelson M, et al.
Lancet Oncol
. 2025 Jan;
26(1):64-73.
PMID: 39756444
Background: Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study...
2.
Jonasch E, Bauer T, Papadopoulos K, Plimack E, Merchan J, Mcdermott D, et al.
Eur J Cancer
. 2023 Nov;
196:113434.
PMID: 38008031
Background: Accumulation of the HIF-2α transcription factor is an oncogenic event implicated in the tumorigenesis of clear cell renal cell carcinoma (ccRCC). In the phase I LITESPARK-001 study, the first-in-class...
3.
Hoimes C, Flaig T, Milowsky M, Friedlander T, Bilen M, Gupta S, et al.
Future Oncol
. 2023 Nov;
20(7):351-360.
PMID: 37994649
What Is This Summary About?: This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or...
4.
Essegian D, Chavez V, Khurshid R, Merchan J, Schurer S
PLoS Comput Biol
. 2023 Nov;
19(11):e1011672.
PMID: 37992014
[This corrects the article DOI: 10.1371/journal.pcbi.1010263.].
5.
Essegian D, Chavez V, Khurshid R, Merchan J, Schurer S
PLoS Comput Biol
. 2023 May;
19(5):e1010263.
PMID: 37235579
PNCK, or CAMK1b, is an understudied kinase of the calcium-calmodulin dependent kinase family which recently has been identified as a marker of cancer progression and survival in several large-scale multi-omics...
6.
Motzer R, George S, Merchan J, Hutson T, Song X, Perini R, et al.
Oncologist
. 2023 Mar;
28(6):501-509.
PMID: 36866412
Background: Lenvatinib plus pembrolizumab showed significantly improved progression-free and overall survival outcomes compared with sunitinib in patients with advanced renal cell carcinoma in the CLEAR study (NCT02811861). Here, we used...
7.
Choueiri T, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa N, et al.
Lancet Oncol
. 2023 Mar;
24(3):228-238.
PMID: 36858721
Background: In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus sunitinib in patients with advanced renal cell carcinoma (data cutoff...
8.
Rudin C, Pandha H, Zibelman M, Akerley W, Harrington K, Day D, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36669791
Background: Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors. Methods: Patients had advanced non-small cell...
9.
Miller R, Luke J, Hu S, Mahabhashyam S, Jones W, Marron T, et al.
J Immunother Cancer
. 2023 Jan;
10(12).
PMID: 36600561
Background: CD73 is widely expressed on immune cells playing a critical role in immunomodulatory functions including cell adhesion and migration, as a costimulatory molecule for T cells and in production...
10.
Essegian D, Chavez V, Bustamante F, Schurer S, Merchan J
iScience
. 2022 Dec;
25(12):105621.
PMID: 36465101
Renal cell carcinoma (RCC) is a fatal disease when advanced. While immunotherapy and tyrosine kinase inhibitor-based combinations are associated with improved survival, the majority of patients eventually succumb to the...